RepliCel Life Sciences - Low-Floater vor Durchbruch in 2017? - 500 Beiträge pro Seite

[techinvestor69]

Nur 14,938,117 Aktien out.

Interessantes Interview:

http://www.cantechletter.com/2017/01/replicel-ceo-lee-buckle…

[techinvestor69]

"We have more significant milestones expected in the next 12 months than the company has had since its inception. This quarter alone will see three separate clinical data announcements in addition to the launch of device manufacturing. Our number 1 priority in 2017 is to build, test and validate the device so I can get a deal done on it with a commercial partner who will be expected to launch the product on the market in 2018 likely first in Europe."

[techinvestor69]

ALERT: RepliCel Life Sciences (TSXV:RP, OTCQB: REPCF)

http://us5.campaign-archive2.com/?u=95719943a1821b57689e12e4…

[Schuro]

Hier mal zwei - wenn auch etwas ältere - Interviews.. Interessanter Wert - scheint, als würde sich jetzt langsam ein Boden ausbilden..





Gruß

[techinvestor69]

RepliCel (RP.V) Should Benefit From Renewed Investor Focus, Sweeping Legislation On Cell Therapy

http://finance.yahoo.com/news/replicel-rp-v-benefit-renewed-…

[techinvestor69]

RCS-01 (Skin Rejuvenation) active licensing discussion with Fujifilm, Mitsubishi Research, Allergan (Japan)

RCT-01 (Tendon Repair) active licensing discussion with Fujifilm, Mitsubishi Research, and Novartis Institute of Biomedical Research

http://replicel.com/wp-content/uploads/2017/01/RepliCel-Pres…

[techinvestor69]

Heute das höchste Handelsvolumen seit September 2016.

100,897 Stück.

Schlusskurs 1,70 CAD.

Wird nicht mehr lange dauern, bis wir die 2,00 CAD herausnehmen.

[techinvestor69]

Auf die Frage, wann Ergebnisse der Trials kommen:

@PJShallow @CCRM_ca @lifesciences_bc Coming very soon now Paul. 2 clinical readouts expected yet this month and another one early March!

https://mobile.twitter.com/RepliCel/status/82763065369273139…

[techinvestor69]

das kommt jetzt etwas überraschend...

REPLICEL LIFE SCIENCES INC. ANNOUNCES BROKERED PRIVATE PLACEMENT

RepliCel Life Sciences Inc. has appointed a syndicate of agents co-led by Echelon Wealth Partners Inc. and Haywood Securities Inc., with participation from Clarus Securities Inc., to undertake a brokered private placement, on a commercially reasonable basis, of up to 1.6 million units at a price of $1.25 per unit.

Each unit will consist of one common share of the company and one common share purchase warrant, with each warrant entitling the holder to purchase one additional common share at a price of $2 per common share for a period of three years from the closing of the offering. Echelon will act as the sole bookrunner for the offering.

All securities issued pursuant to the offering will be subject to a statutory hold period expiring four months and one day after closing of the offering. Completion of the offering is subject to a number of conditions, including without limitation, entry into an agency agreement with the agents and receipt of all regulatory approvals, including approval of the TSX Venture Exchange.

Proceeds of the offering are anticipated to be used for clinical trials, research and development, device manufacturing and testing, and general working capital.

We seek Safe Harbor.

[techinvestor69]

Podcast mit CEO

http://business.financialpost.com/midas-letter/podcast-repli…

[freybel]

Patente....

http://finance.yahoo.com/news/replicel-announces-european-pa…

[techinvestor69]

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

RCI-02, RepliCel's nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections

VANCOUVER , Feb. 9, 2017 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing unique biologic products for pattern baldness and thinning hair, aging and sun-damaged skin, and chronic tendon degeneration, today announced the granting of two patents in Europe related to its multi-needle dermal injection technologies.

The first patent, European Patent No. 2623146, has been validated in a total of fourteen national countries, including Austria , Belgium , Denmark , Finland , France , Germany , Ireland , Italy , the Netherlands , Norway, Spain, Switzerland , Sweden and the United Kingdom. The second patent, European Patent No. 2809381, will also be validated in a number of European countries in the near future.

The first device being developed under these patents, RCI-02, is designed for injecting hyaluronic acid ("HA") and other products as dermal fillers. The device is also being developed for the injection of RepliCel's RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the technology and device will be optimized for other injectables such as drugs, biologics, vaccines, fat grafts, etc.

"These patents are an important milestone for the Company as it underpins the near-term commercial value of RCI-02 for the delivery of other injectables beyond our own products. RCI-02 coupled for the injection of dermal fillers and other aesthetic treatments represents an early opportunity for licensing and revenue," stated RepliCel CEO Lee Buckler . "This year we will build and test commercial-grade functioning prototypes with the goal of having it ready for a CE-mark application and potential market launch in 2018. Ongoing discussions with several multinational companies about potential commercial partnerships for the device give us confidence this represents one of RepliCel's next licensing deals."

Overall benefits of this next-generation dermal injector technology are anticipated to include improved handling, reduction or elimination of the need for local anesthetic, quicker procedure times, improved patient experience, and a significant expansion of the areas that can be addressed with dermal fillers due to the ability to conduct broad, shallow, and evenly-dispersed injections. Additionally, the device's simplicity and programmability is expected to enable less-experienced injection specialists to deliver predictable and consistent outcomes.

"RCI-02 was originally conceived to deliver our cellular products; however, we believe this device will have a profound impact on all dermal injections – particularly in the cosmetic dermal injection market. For the first time, the dermatology sector will be given a device, RCI-02, which enables clinicians unprecedented reliability, reproducibility, and programmability of three dimensional skin injections," commented Dr. Rolf Hoffmann , RepliCel's Chief Medical Officer, who is a practicing dermatologist and is the visionary for the RCI-02 injector. "Dermatologists have been hindered for years by a single needle syringes' inability to precisely deliver approved dermal fillers into fine wrinkles of the face, décolleté, and hands. RCI-02 is designed to address these unserved markets while also improving on current markets by enabling precise and repeatable delivery of injectable substances. RCI-02 will enable clinicians to better control injection consistency while also enabling less skilled clinicians to undertake these procedures with the desired results."

"In addition to the near-term commercial opportunity RCI-02 represents for revenue generation, we believe ensuring the optimal and controlled delivery of our cell-based products will be an important component to the commercial value we are creating around the development of our products for both aging or sun damaged skin and pattern baldness," commented Lee Buckler , CEO.

About RCI-02

The RCI-02 injector was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes.

[techinvestor69]

Vielleicht will RP noch den ein oder anderen Wirkstoff/Technologie einlizensieren. Ansonsten würde das Placement kaum Sinn machen.

[techinvestor69]

"...

With this financing in place, not only did he raise the necessary funding to complete both his clinical trials but he also raised enough money to move forward with their medical device, the one that garnered so much attention during their previous roadshows. That device (which you can read about in more detail here: http://replicel.com/product-pipeline/rci-02-dermal-injector/… could potentially reward RepliCel with a major transaction over the next twelve months – one that would, if successful, merit an upfront cash payment that could dwarf their current market cap.

...

After meeting with a number of these investors at the JP Morgan Biotech Conference last month, the excitement started to roll again and more investors wanted a piece of what could become one of the most exiting biotech revivals of the decade. With this in mind, Lee announced a small $2 million brokered private placement led by Echelon Partners which included Haywood Securities and Clarus to accommodate some of these investors which has again seen a surge of demand over night.

It is very important to note that this is a STRATEGIC ROUND - there’s no doubt about it. Lee didn’t want to dilute his shareholders at these levels but there were a number of very smart value-add investors that are being let in because they can help take this company to new heights.

By sticking to the story and their constant belief in its future, they now have a clear path to success and they’re about to reap the rewards. Lee Buckler is one of the most tenacious, hardworking and determined CEO’s I’ve ever met and I’m excited to be covering this company for years to come. There is nothing more important to Lee than to create value for his shareholders, and from what I’m hearing, 2017 is going to be an extremely exciting year!

In case you missed it, the team added capital markets executive Hugh Rogers to their board to help market and expose their story to the world and help a number of strategic initiatives. Hugh was instrumental in taking one of our favorite Alphastox features, 3D Signatures (TSXVXD) from $0.35/share to over $1.13/share in a just a few months and he plans to do to the same thing here. He’s got an incredible rolodex and is fully focused on building value for RepliCel investors.

...

With data from two phase one trials about to be announced and a medical device currently being built, expect a ton of news flow over the coming quarters and a lot more exposure out of the U.S. At $1.68/share, RP.V is just getting started. Remember, $1.68/share is only $0.168/share pre-consolidation. The stock used to trade well into the $0.30-$0.40/share range comfortably when they were desperate for money, which would be equivalent to $3-$4/share today.

...

The company is just starting to expose the story to new investors all over the continent and it has already been picked up by a number of different press outlets. Here’s a list of some of the third-party articles that have been written on RepliCel over the last couple months:

http://business.financialpost.com/midas-letter/podcast-repli…

http://investingnews.com/daily/life-science-investing/biotec…

http://advisor-access.com/featured-companies/replicel-life-s…

http://scr.zacks.com/News/Press-Releases/Press-Release-Detai…

http://www.cantechletter.com/2017/01/replicel-ceo-lee-buckle…

ESPN with Bill Daughtry
http://www.espn.com/espnradio/newyork/play?id=18570324 (at t…

Total Tutor with Neil Haley
http://www.blogtalkradio.com/totaltutor/2016/11/28/lee-buckl…

CBS with Jake Long
http://download.podcast.play.it/media/d0/d0/d1/dD/dI/d6/dV/1…

So, what are the catalysts to watch over the next three months?

Clinical data from both their RCT-01 (chronic tendon injury) and RCS-01 (aging and sub-damaged skin) clinical trials mid-way through Q1 (all the trial participant data needed for this announcement has been collected and is now being prepared for third-party analysis)

In 2012, when they announced the safety and 6-month clinical efficacy data from their phase 1 study of RCH-01 (pattern baldness), they knew that in 2017 they would have 5-year safety data and both 12 and 24-month efficacy data which was all locked until the completion of the 5-year trial (all the trial participant data needed for this announcement has been collected and is now being prepared for third-party analysis)

While the dermal injector (RCI-02) program was almost completely static over 2016 given their lack of funds, they have now re-activated and prioritized the project to complete manufacturing of functional and tested prototypes in 2017 sufficient to support their filing of the CE mark application required to sell the device in Europe with label approval for injection of hyaluronic acid-based dermal fillers

The randomized, placebo-controlled trials in tendon and skin repair will deliver informative data to support the Company’s story, prioritize future clinical development, and guide critical decisions about designing future multi-centre, clinical trials designed to provide statistically significant clinical data and address questions related to dosing, treatment frequency, etc.

By 2018, the company expects to be posting revenue from the dermal injector.


...

Quelle: Alphastox Newsletter

[Jano82]

Antwort auf Beitrag Nr.: 54.303.887 von techinvestor69 am 13.02.17 08:31:15

Hallo erst mal . Ich bin durch Zufall auf diese Aktie gestoßen. Das was ich auf die schnelle gefunden habe klingt auch nicht schlecht . Der Injector scheint ja auch Interesse geweckt zu haben . Ich habe nur keine Ahnung ob man damit wirklich genug Geld verdienen kann . Die restliche Pipeline kann ja auch durchaus interessant werden aber bis dahin ist es ja noch ein ganzes Stück

[techinvestor69]

Biotechaktien laufen nicht erst, wenn die Wirkstoffe vermarktet werden. Das Device bringt ab 2018 Umsätze und vorher fetten Lizenzdeal mit Upfrontzahlung in diesem Jahr.

[Jano82]

Antwort auf Beitrag Nr.: 54.311.995 von techinvestor69 am 13.02.17 23:51:41

Da hast du natürlich recht . Ich tue mich im Moment nur schwer damit das Potenzial der Restlichen Pipeline abzuschätzen

[techinvestor69]

@Jano - am besten mal in die verfügbaren Research-Reports oder die Corporate Presentation reinschauen, da stehen Marktzahlen drin oder Dr. Hoffmann anrufen, der sitzt in Deutschland und spricht auch deutsch.

[Jano82]

Antwort auf Beitrag Nr.: 54.315.739 von techinvestor69 am 14.02.17 13:26:30

Das werde ich auch tun . Meine Aktien Käufe wahren eigentlich alle schon getätigt und wie gesagt ich bin durch Zufall auf diese gestoßen und finde sie sehr interessant aber komme auf Grund von Arbeit und kranken Kind gerade nicht dazu mich tiefer damit zu beschäftigen wie ich es normalerweise tue . Denke werde mal kleine Posi zulegen und wenn ich mehr Infos habe evtl zukaufen . Danke für die Info über die Möglichkeit persönlich Kontakt aufzunehmen

[techinvestor69]

The Next Biotech Winner could be Replicel

Dr. Kal Kotecha Dr. Kal Kotecha, PhD
9 days ago

This emerging biotech company is harnessing the incredible power of your body’s cells to regenerate damaged tissue in not one, but three major conditions.

Results from ALL THREE clinical trials are expected soon. Positive results on ANY ONE trial has the potential to reward shareholders.


Kal Kotecha, PhD.
Techmoney360.com

On a recent Friday, tiny Aquinox Pharmaceuticals was trading at under $2.00; at $1.84, to be specific.1

Then something incredible happened.

The company released positive mid-stage clinical trial results on their bladder pain drug.

Twitter went mad.

The stock took off.

By that afternoon, shares had traded up as much as 500%.

Over the next two weeks nearly 18 million shares changed hands – roughly 90 times the stock’s 30-day average.

By that Friday Aquinox hit a high of $22.13, a gain of 1,103%.

Another stock, Celator Pharmaceuticals, recently jumped over 500% on positive Phase 3 results. That move took just five days.

Then Incyet Corp. went from $2.54 to $131 – a leap of 5,057% -- on a series of positive news.

And a whole slew of others have rewarded investors just as much.

Spectacular profits, to be sure, and not as rare as you might think.

In fact, when a pharma or biotech announces positive news its stock often takes off like a bullet.

“It’s not uncommon for trial data…to trigger sharp share-price swings for small-cap pharmaceutical companies.” – MarketWatch, Aug 10, 2015

The trick, of course, is finding the stocks that are about to soar.

The ones about to release positive news.

That’s why you should know about a specific event in the next few weeks that could send one small biotech company stock higher.

I feel it is one of the more promising opportunities in today’s market.

The company has three innovative therapies in clinical trials.

All three of them have progressed on extremely positive pre-clinical, Phase 1, or Phase 2a trial data.

Now the company is set to release new trial results or progress for all three therapies in coming weeks.

“Biotech stocks, taken as a whole, have absolutely crushed the market over the trailing five-year period.” – Motley Fool

A small company with THREE therapies in trial is “unique” in biotech or pharma investing.

Good news on any one trial could mean share price gains for investors.

But if they come back with good news on all three?

You can just imagine the sky could be the limit!

The company’s stock trades at under $2.00 today, but could potentially trade much higher in a short time.

This dynamic company with potentially breakthrough therapies is relatively small today, but that’s what makes it so attractive.

This is not an opportunity you want to miss. The time to research this company is now.

The company’s name is RepliCel Life Sciences, and here is some of what you need to know about them.

RepliCel Life Sciences (TSX.V-RP | OTCQB-REPCF) is introducing a revolutionary way to “self-repair” damaged tissues with your own cells.

RepliCel is an emerging player in the hot new regenerative medicine market.

Regenerative medicine is the process of restoring damaged, diseased, or aging tissue through the use of drugs, biologics, devices, or cell therapy.

Unlike nearly all medicine today, regenerative medicine aims to cure disease rather than manage symptoms.2

The Mayo Clinic calls regenerative medicine “game-changing,” saying that the field offers “solutions and hope for people who have conditions that today are beyond repair.3

RepliCel’s expertise is in a specific branch of regenerative medicine called cellular therapy.

Cellular therapy is the process by which living cells are injected into a trauma site in order to regenerate healthy tissue.

The company’s game-changing technology is a way for your body to repair itself by replicating healthy cells.

Mahendra Rao of the National Institutes of Health says that such cell therapies “could be paradigm-shifting for the healthcare field.4

And Wendell Lim, PhD, director of the UCSF Center for Systems and Synthetic Biology, says that today we are “on the cusp of a revolution” because of emerging cell therapy technologies.5

Treating disease and aging by applying living cells could eliminate the need for drugs and radically invasive surgeries.

The global cell therapy industry is already more than $1 billion.6

And it is projected to grow by 17,000% by 2020, to $170.15 billion!7

Chris Mason of the Advanced Centre for Biochemical Engineering says that the industry has “unlimited potential."8

It is already starting, in such fields as heart disease, cancer treatment, and immune disease. Companies like RepliCel (TSX.V-RP) are racing toward dominance in a world desperately in need of new treatments for age-old conditions.

RepliCel is aiming for a fast road to commercialization while magnifying shareholder value.

The three therapies that RepliCel is introducing are advanced cell-based products for aging skin, hair loss, and damaged tendons.

All three focus areas are strategically designed to make RepliCel’s entry to the marketplace quick and easy. There are four reasons.

Compared to, say, heart disease or cancer, there is low technological risk to each of the therapies.9
What’s more, those markets are currently underserved with ineffective therapies.
There are clear clinical indications for treatment in each case.
And finally, commercial success is not dependent on successful reimbursement negotiations with insurance companies.


RepliCel says:

“On the technical level, we’re not asking these cells to do anything other than what they naturally do, or be anything more than they are.

“These are adult, somatic cells derived from the patient which we simply isolate and grow. We’re not differentiating, genetically modifying, or manipulating these cells in any way."

There is also a strong connection between the therapies for aging skin, hair loss, and damaged tendons.

The specific cells used in RepliCel’s therapies are easy to collect, grow well in culture, and are highly functional.

Healing your body with collagen

The connection between RepliCel’s three therapies is collagen.

RepliCel’s proprietary science is based on the unique properties of collagen to heal tissue and grow hair.

Collagen is what holds your body together.

After water, it is the most common substance in your body.

Collagen also plays a big part in renewing cells, and is responsible for maintaining the strength and elasticity of tendons, skin, and hair.

But your body’s ability to produce collagen decreases from around age 30. This is what gives you wrinkles; causes your hair to diminish, become fragile, or lose color; and leads to weakness in your tendons and ligaments.

RepliCel aims to improve conditions related to diminished collagen.

Their method is to generate new collagen-producing cells in a laboratory and then inject them into targeted areas, where they regenerate healthy new tissue.

They are able to do this because of…

A revolutionary discovery by RepliCel’s scientists.

Fibroblasts are the cells in connective tissue that produce collagen.

Importantly, the scientists discovered that the fibroblasts in hair follicles are about five times more prolific than skin cells in their production of collagen.11

RepliCel’s scientists hypothesized that the injection of these collagen-producing cells into damaged tissue could induce the growth of healthy new tissue.

Pre-clinical studies proved the hypothesis correct, and the company moved quickly to patent their findings and begin clinical trials.

Those trials are new underway for the rejuvenation of aging skin, hair loss, and torn or damaged tendons.

Together, those three markets represent…

$11 billion in pent-up demand

There are currently no completely effective treatments for rejuvenating aging skin, repairing damaged tendons, or reversing hair loss.

Doctors do their best with the surgeries and products available today, but those surgeries and products fall short.

Many are also invasive and painful.

The American Hair Loss Association says that, “Unfortunately, 99% of all products being marketed in the less than ethical hair loss treatment industry are completely ineffective for the majority of those who use them.12

Current tendon repair methods are equally ineffective. A clinical review of treatment methods published in Clinical Orthopaedics and Related Research concludes that “The ideal treatment for tendinopathy remains unclear.13

Likewise, skin regeneration treatments are ineffective in promoting satisfying skin regeneration.14

Yet even though current treatments are ineffective, consumers spend billions of dollars on treatments.

The victims of hair loss spend $3 billion a year searching for effective solutions in surgery, creams, or drugs.15

Skin rejuvenation is a $3.2 billion market, mostly for Botox and hyaluronic acid fillers.16

And annual expenditures on tendon repair exceed $5 billion every year.17

If clinical trial results show the same effectiveness as they have in early research, RepliCel could quickly dominate these markets.

The product that could hit the market first is the company’s cell therapy for hair loss.

More effective than any drug or topical treatment now on the market!

Hair transplant surgery has a number of problems, including a limited number of hair follicles available to harvest, the skill of the surgeon, and prohibitive cost and pain.

And Rogaine® and Propecia®, the two baldness treatments on the market today, regrow hair in only around 26% of subjects.18

Plus, if Rogaine or Propecia treatments are stopped, the new hair falls out.

In comparison, in pre-clinical and Phase 1 studies RepliCel’s cell therapy treatment resulted in new hair growth in an outstanding 63% of test subjects.19

The procedure is a simple cell injection that even technicians can perform, and there is no limit to the number of cells that can be grown to regenerate new hair follicles.

The hair rejuvenation therapy is advancing quickly toward commercialization, thanks not only to the science, but to a dynamic partnership with many benefits to RepliCel.

RepliCel is partnering with the world’s fourth largest cosmetics and personal care company to bring its proprietary hair restoration therapy to market.

RepliCel’s strategy is to be a discovery and development company.

That means they discover and develop cell therapies through pre-clinical and early clinical trial stages, then partner with larger companies with the infrastructure and capital to bring those products to market.

And the strategy is paying off. Global giant Shiseido, the fourth largest cosmetics and personal care company in the world, is partnering with RepliCel to bring the company’s first product to market.

Shiseido has built an entirely new facility in Kobe, Japan, for research and development on the hair restoration therapy with RepliCel’s collaboration.

What’s more, commercialization could happen as soon as early 2018, based on two factors.

First, RepliCel has released positive pre-clinical and Phase 1 trial results, including efficacy.

They have already proved that the therapy works.

Second, Japan, where RepliCel and Shiseido are conducting Phase 2 trials, has introduced new regulations that allow companies to market their products during Phase 2 trials.

This extremely important development means that RepliCel’s hair restoration therapy could already be speeding to market.

New regulations to speed cell therapies to market could benefit RepliCel.

In November of 2014 Japan passed a new act that lay the foundation for the country to become a world leader in regenerative medicine and cellular therapy.

The new regulations accelerate the approval of regenerative therapies, enabling companies to receive marketing approval and generate revenue from regenerative therapies while trials are being conducted. In contrast, in the U.S. clinical trials must be completed before the FDA grants approval for commercializing the product.


Now, based on small trials that show safety and predict efficacy, a company can get conditional commercialization approval for seven years. Ultimate efficacy will be determined by the market.

That is a monumental advance, and one that will help propel RepliCel to quickly build shareholder value.

“A cure for baldness doesn’t leap to mind when one ponders the next advance in stem-cell research, but whoever manages to do it could become very rich.” – Erin Ellis, National Post

Shiseido is paying RepliCel $35 million in upfront fees, sales milestones, and royalties for marketing rights in the Japan, China, Korea, and ASEAN nations.

RepliCel already conducted a Phase 1-2a open-label trial on the product. Now a clinical trial has commenced in Japan, with expected readouts (data) just around the corner, this year.

Those readouts would give RepliCel and Shiseido the potential to COMMENCE MARKETING THE PRODUCT in Asia.

Rollout to North America, Europe, and other areas are expected.


Patented therapies protect RepliCel’s market.

RepliCel is advancing quickly towards commercialization on all three of its therapies.

It has already successfully patented its hair regeneration therapy in the United States, Japan, Australia, and the European Union, with other jurisdictions pending.20

Patents cover RepliCel’s unique methods for extracting follicle-derived stem cells, and the growth and use of these cells for the treatment of a variety of medical conditions.21

Patents are pending for the company’s tendon therapy, as well.

What’s more, RepliCel has licensed a family of patents relating to the composition and use of cells in the treatment of tendons and ligaments.

A patent has also been granted by the European Patent Office for the proprietary dermatology injector device used in the company’s skin rejuvenation therapies. Patents are pending in other jurisdictions.

These patents represent one-of-a-kind therapies that have no competitors in the marketplace.

They are the foundation of a company with the potential to answer the pent-up demand for effective treatment of collagen-rich tissues, including skin, hair, and tendons – the low-hanging fruit of the cell therapy market.

Results and progress are expected on all three therapies in the first quarter of 2017.

There are many reasons to look at RepliCel (TSX.V-RP) as an investment.

But there’s one very strong reason to look at the company NOW.

All three of RepliCel’s breakthrough therapies are currently in clinical trials.

And clinical results or progress are expected on all three in just a matter of a few weeks.

You saw at the beginning of this report how positive news on drug or therapy development tends to push stock prices dramatically higher.

Now imagine what could happen if RepliCel (TSX.V-RP | OTCQB-REPCF) has THREE positive reports within days or weeks of each other…

Here is what is expected to be reported, according to company announcements:

If you’re looking for potential profits in the biotech space, this could be where you find them.

Take it upon yourself to research RepliCel and consider a well-timed investment today.

It’s important you do your own thorough due diligence on every stock in which you invest!
To your investing success,

Kal Kotecha, PhD ~ Editor and founder, TechMoney360.com

Kal Kotecha, PhD, is the editor and founder of TechMoney360. He is a noted stock picker and frequent contributor to Stockhouse, Equities.com, the Aureport, Streetwise Report, Kitco.com, and 321gold.com. Dr. Kotecha also lectured Economics at the University of Waterloo and Niagara College, where he was voted Professor of the Year 2013/2014. He holds an MBA in Finance and a PhD in Business Administration.

Some of his recent picks include:

Keek (TSX.V-KEK), an e-commerce live streaming platform that soared from $.25 a share to $2.40 share, a gain of 860%
First Global Data (TSX.V-FGD), a tech stock that jumped from $.12 to $.50, a gain of over 300%
New Age Farm Inc. (TSX.V-NG), a marijuana stock that took off from $.09 to $.36, giving investors a gain of 300%



References:

1 July 31, 2015
2 Cell therapy industry: billion dollar global business with unlimited potential, C. Mason et al, Regenerative Medicine, May 2011, Vol 6 (3), 265-272 http://www.futuremedicine.com/doi/abs/10.2217/rme.11.28
3 About Regenerative Medicine, Centers for Regenerative Medicine, Mayo Clinic http://www.mayo.edu/research/centers-programs/center-regener…
4 The Little Cell That Could, M. Scudellari, The Scientist, July 1, 2012 http://www.the-scientist.com/?articles.view/articleNo/32272/…
5 Will Cell Therapy Become a ‘Third Pillar’ of Medicine?, J Norris, UCSF News center, April 3, 2013 https://www.ucsf.edu/news/2013/04/104816/will-cell-therapy-b…
6 The Impact of Market Volatility on the Cell Therapy Industry, D. Brindley et al, Cell Stem Cell, Nov 2011, Vol 9 (4) 397-401 http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(11)00…
7 Stem Cells Market Size to Reach $170.1 Billion by 2020, Grand View Research, Sept 2015 https://www.grandviewresearch.com/press-release/global-stem-…
8 Cell therapy industry: billion dollar global business with unlimited potential, C. Mason et al, Regenerative Medicine, May 2011, Vol 6 (3), 265-272 http://www.futuremedicine.com/doi/abs/10.2217/rme.11.28
9 Cell Therapy is “Hair Raising” in a Good Way, G Dutton, RepliCel http://replicel.com/recent_coverage/cell-therapy-is-hair-rai…
10 NBDS Fibroblast Therapy – Treatment for Chronic Tendinosis, RepliCel http://replicel.com/product-pipeline/rct-01-tendon-repair/
11 Ibid
12 American Hair Loss Association http://www.americanhairloss.org/hair_loss_treatment/
13 Treatment of Tendinopathy: What Works, What Does Not, and What is on the Horizon, B Andres, et al, Clinical Orthopaedics and Related Research, 2008, Vol 455, 7 1539-1554 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2505250/
14 Chitin and Chitosan Derivatives: Advances in Drug Discovery and Developments, S. Kim, ED, 2013, CRC Press, page 456, 24.3.1.4
15 Hair Loss Treatment & Removal in the US, IBIS World, January 2016 http://www.ibisworld.com/industry/default.aspx?indid=1720
16 Aesthetic Market Forecast, M. Moretti http://digital.miinews.com/article/2009_Aesthetic_Market_For…
17 Regenerating Medicine, Kensey Nash, http://extras.newswire.ca/canaccordgenuity/20120207/pdf/kens…
18 DailyMed, National Institutes of Health https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.c…
19 Further Analysis Reveals Double Digit Hair Growth in RepliCel’s First-in-man Clinical Trial, RepliCel, May 17 2012 http://replicel.com/further-analysis-reveals-double-digit-ha…
20 RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology, RepliCel, January 13, 2014 http://replicel.com/replicel-receives-japanese-patent-coveri…
21 RepliCel Intellectual Property http://replicel.com/technology/intellectual-property/

Disclaimer
© 2017 TechMoney360

TechMoney360 Newsletter: TechMoney360’s Newsletter is published as a copyright publication of TechMoney360 (TM3). No Guarantee as to Content: Although TM3 attempts to research thoroughly and present information based on sources we believe to be reliable, there are no guarantees as to the accuracy or completeness of the information contained herein. Any statements expressed are subject to change without notice. TM3, its associates, authors, and affiliates are not responsible for errors or omissions. Consideration for Services: TM3, its editor, affiliates, associates, partners, family members, or contractors may have an interest or position in featured, written-up companies, as well as sponsored companies which compensate TM3. TM3, its owner and affiliates/associates may buy/sell and trade the company’s stock written up/video created on from time to time. TM3 has not been paid by the company for this feature article. However, multiple conflicts of interests may exist. Therefore, information provided here within should not be construed as a financial analysis but rather as an advertisement. The author’s views and opinions regarding the companies featured in reports are his own views and are based on information that he has researched independently and has received, which the author assumes to be reliable. No Offer to Sell Securities: TM3 is not a registered investment advisor. TM3 is intended for informational, educational and research purposes only. It is not to be considered as investment advice. Subscribers are encouraged to conduct their own research and due diligence, and consult with their own independent financial and tax advisors with respect to any investment opportunity. No statement or expression of any opinions contained in this report constitutes an offer to buy or sell the shares of the companies mentioned herein. Links: TM3 may contain links to related websites for stock quotes, charts, etc. TM3 is not responsible for the content of or the privacy practices of these sites. Release of Liability: By reading TM3, you agree to hold TechMoney360, its associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.

Read more at http://www.stockhouse.com/news/newswire/2017/02/03/the-next-…

[Jano82]

Antwort auf Beitrag Nr.: 54.342.499 von techinvestor69 am 17.02.17 00:12:34

Hallo Tech . Du bist besser in der Aktie informiert wie ich . Gibt es einen Grund für diesen Kurssturz ? Ich kann nichts finden Gruß Jano

[Schuro]

Antwort auf Beitrag Nr.: 54.405.628 von Jano82 am 24.02.17 17:06:47

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement


http://www.wallstreet-online.de/nachricht/9349711-replicel-l…

[techinvestor69]

@Jano - die Profis shorten die Aktie vor Ende der Sperrfrist. Stücke wurden zu 0,52 ausgegeben.

[Jano82]

Antwort auf Beitrag Nr.: 54.443.325 von techinvestor69 am 01.03.17 20:10:11

Dann warte ich mal noch etwas mit meinen nachkauf

[techinvestor69]

REPLICEL PURSUES NON-DILUTING GRANT FUNDING TO ACCELERATE VALUE CREATION AND COMMERCIALIZATION

RepliCel Life Sciences Inc. has retained The FreeMind Group, a premier international firm that assists life science organizations in securing non-dilutive financing from granting agencies and private foundations. RepliCel aims to secure non-dilutive capital to support research, clinical development and/or manufacturing priorities to accelerate value creation and the commercialization of its products.

"We have a number of strategic clinical and non-clinical projects which are ideally positioned for external collaborations and non-dilutive funding. These include basic research, manufacturing optimization, product development and clinical objectives which have the potential to create significant intellectual property and shareholder value," stated RepliCel's president and chief executive officer, R. Lee Buckler. "FreeMind has a proven track record and commitment to success-based remuneration that convinces us they will bring significant value to our programs. I look forward to updating our shareholders over the coming months with their progress."

[techinvestor69]

REPLICEL'S PHASE 1 CLINICAL TRIAL FOR HAIR LOSS SUCCEEDS IN MEETING PRIMARY ENDPOINTS

RepliCel Life Sciences Inc. has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness).

The Company reports the trial succesfully met its endpoints and sets the stage for next steps in the ongoing research and development of its product, RCH-01, for the treatment of male and female androgenetic alopecia. "As we march toward commercialization of this product based on this first-in-human data, our aim is to revolutionize the way we prevent, treat, and even reverse hair loss," stated RepliCel President and CEO, R. Lee Buckler.

Safety

The five-year trial data set has confirmed the complete safety profile of a high-dose of dermal sheath cup cells (DSCC) for patients with pattern baldness due to androgenetic alopecia.

These DSCC form the basis for the Company's RCH-01 product. The long-term safety of DSCC injections was demonstrated through multiple physician, patient and independent measures of local and systemic tolerance including evaluation of adverse events with respect to causality, incidence, severity and seriousness. No serious adverse events were reported over the entire 60.5-month follow-up period of the trial. Local injection tolerance was confirmed with only a few minor scalp irritations reported around injection sites that resolved quickly soon after injection. Furthermore, histopathological evaluation of injection site biopsies taken six, 12, and 24 months after injection did not reveal any pathology that was suggestive of tumour, granuloma or foreign body formation. An analysis of injection site biopsies taken 60.5 months after injection is currently ongoing with results expected in the next few weeks. Long-term systemic safety of RCH-01 was also confirmed as none of the systemic adverse events reported during the extended safety evaluation were related to treatment.

Indications of Potential Efficacy

The trial was designed to gather data related to the product's potential efficacy through 24 months post-injection, but was not designed for statistical significance related to any efficacy endpoints. The efficacy data collected from all 19 patients, while not statistically significant, provides useful and potentially exciting insights into the product's potential for the treatment of those with androgenetic alopecia.

"We have a much greater understanding and opportunity for further insights from the hair density responses recorded in this first-in-human trial," stated RepliCel President and CEO, R. Lee Buckler. "This data will feedback into our R&D programs and help us develop the best possible product and treatment protocol for men and women suffering from androgenetic alopecia."

The seven top-tier responders in the trial saw >10% increase in hair density at six months post-injection (see May 17, 2012 announcement). At 24 months, the average hair density increase for these same seven participants was 8.3% over baseline, and three of these seven trial participants maintained a >10% increase in density over baseline. The largest increase in hair density over baseline observed in this group was a 21% increase at 24 months.

The top 10 participants reported at least a 5% or greater increase in hair density at six months post-injection with an average increase of 11.8% (as reported in the May 17, 2012 announcement). This group demonstrated a sustained response at 24 months which averaged a 4.2% increase over baseline hair density. While there was a high degree of variability in hair density between individual participants at 24 months post-injection compared to baseline, an overall stabilization of hair loss was observed among all the patients treated per protocol.

Management Commentary

"The purpose of collecting efficacy data in these early-stage trials," stated RepliCel's Clinical Consultant, Darrell Panich, "is for our clinical team and management to obtain data that can be used to inform basic decisions about further development, provide provocative insights into the product's potential, and three-fourths perhaps most importantly three-fourths provide useful feedback which we can use to drive decisions about process and product development, ongoing research, and future clinical trial parameters."

"We are very pleased with the unquestionable safety profile of RCH-01," stated RepliCel's co-founder and Chief Medical Officer, Dr. Rolf Hoffmann. "Five-year safety follow-up is rare for cell therapy products and demonstrates our commitment to the highest quality of clinical research. Furthermore, the efficacy signals we see validate the research and development strategy we have had in place since we saw the six-month post-injection data in 2012."

Hoffmann continued: "Over the past 36 months, we have invested a great deal in both basic research and manufacturing optimization which we believe will be critical to minimizing batch-to-batch variability and further improving efficacy. We have invested in process and product development initiatives including a modified tissue culture technique, improved culture media with addition of 12 new ingredients, introduction of a cell activity promoting step, and cryopreservation storage to improve cell stability and viability. We believe these programs have already resulted in a significantly more robust and better-defined product than the one used in this trial by many measures and look forward to translating our continued R&D into next-phase clinical trials in due course."

"This trial involved the injection of a very high dose of DSCC in order to identify any potential toxicity ceiling in accordance with the primary safety objectives of the trial. The efficacy data we saw in this trial, together with recent animal research data, suggests that long-term survival of injected cells improves both with smaller dose size and with several sessions of injections spaced-out over a set time course to cumulatively increase injected cell numbers," stated RepliCel's co-founder and Chief Scientific Officer, Dr. Kevin McElwee. "We expect cell number and long-term cell survival to be correlative with hair density efficacy. Next-phase trials will be designed to test repeated injection sessions with smaller cell doses than were used in this study."

"Furthermore," continued McElwee, "with this 24-month post-injection data, and the availability of patient biopsy material and DSCC, we are now able to commence gene expression analysis with a goal of identifying the differences between products which result in superior responses and those that produce less-than-optimal responses. Ultimately, the goal here is to correlate and optimize cell dose and use repeat treatment sessions to achieve peak efficacy in terms of increased hair density."

"In summary," stated RepliCel's President and CEO, R. Lee Buckler, "we are very pleased with the results of this first-in-human study and are excited to move this product forward into the next phases of development."

Buckler concluded: "The analysis of data collected from this study, and the direction it gives our research and development programs, will support further optimization of the RCH-01 treatment to be evaluated in future phase II clinical trials. This data, combined with results expected next year from the Shiseido-funded study ongoing in Japan, will support future negotiations with regulators and licensees as we march toward RCH-01 commercialization. Additionally, we are confident that using RepliCel's RCI-02 injection device (currently under development) in future trials will better control the dose, distribution, and depth of injections to the scalp of study participants. We expect this to further positively impact the product's efficacy and the uniformity of response."

About the RCH-01 Clinical Trial (2011 - 2017)

The TS001-2009 first-in-human clinical trial was designed to test the safety and efficacy of dermal sheath cup cells (DSCC are the basis for the Company's current RCH-01 product) in men and women with androgenetic alopecia. The primary protocol objective of the study was to assess the local (at treatment sites) safety profile of injections. Secondary protocol objectives were to assess systemic (whole-body) safety and local efficacy (hair growth at treatment sites). A total of 19 subjects (10 male and nine female) were recruited for the trial and all of them completed 24-month post injection follow-up visits. Seventeen of those patients went on to complete a full five years of extended saftey evaluations to provide information on the long-term safety of DSCC injections. For further details about the trial design, endpoints, etc see https://www.clinicaltrials.gov/ct2/show/NCT01286649.

[Chancen1904]

das ist jetzt nicht so berauschend... okay... es scheint sicher zu sein, aber das Ergebnis ist nicht so prall, wie erhofft

[techinvestor69]

@Chancen1904 - was für Zahlen hast Du denn erwartet?

[techinvestor69]

REPLICEL'S SUCCESSFUL RCT-01 TENDON REPAIR CLINICAL TRIAL SHOWS SIGNS OF HEALING CHRONIC TENDON PROBLEMS

RepliCel Life Sciences Inc. has released compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel's Type 1 collagen-expressing, hair-follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis.

The clinical trial met its goal of establishing a complete safety profile at 6 months and showed no serious adverse events related to the study treatment or injection procedure.

Additionally, each of the treated participants, all of whom suffered chronic tendon pain and loss of function over an extended period of time with no recovery from standard treatments, showed numerous clinically important improvements by various measures including tendon composition, blood supply, physical function and pain sensation.

"Chronic tendinosis is a state of tendon degeneration that is very difficult to reverse, as evidenced by the many therapies used to try and treat it," stated Dr. Ross Davidson, an orthopedic surgeon, former clinical professor at the Department of Orthopaedics at the University of British Columbia, and past head physician and orthopaedic consultant for the Vancouver Canucks (of the National Hockey League (NHL).

"This study shows exciting clinical improvements in patients with clinically diagnosed chronic Achilles tendinosis who were unresponsive to standard treatments, and who had suffered for many months (in some cases, years) with frequent pain and loss of function. Not only did the study show several clinically important improvements in pain and function scores, but several ultrasound measures clearly demonstrate a marked improvement in tendon structure; something rarely seen in patients with this condition," said Davidson.

"With further clinical studies, this new technology could represent a cutting-edge advancement in kick-starting a healing process that results in tendon regeneration. For the first time, we may have a treatment that shows signs of reversing the underlying problem, versus just treating the symptoms. This could be a game-changer in sports medicine," Dr. Davidson concluded.

The most clinically material improvements observed from the study are summarized as follows:

VISA-A Scale of Achilles Tendon Injury Severity Participants treated with RCT-01 in the per protocol population who completed the VISA-A evaluation 6 months after receipt of injections showed clinically relevant signals of healing including an overall 15.3% improvement in total score compared to baseline. Two patients showed select measures of near-complete recovery in function (by VISA-A scoring).

VAS Scale of Pain Severity Four out of five participants treated with RCT-01 who completed questionnaires 6 months after injection showed clinically relevant signals of improvement in pain on loading (running/jumping) based on VAS score. Average improvement in VAS score for the four participants was 62.9% over baseline VAS score.

Three out of five participants treated with RCT-01 who completed questionnaires 6 months after injection showed improvement in pain on palpation based on VAS score. Average improvement in VAS score for the three participants was 55.2% over baseline VAS score.

Two patients showed select measures of near-complete elimination of pain (by VAS scoring).

"This trial was to show the safety of injection of hair follicle-derived non-bulbar dermal sheath cells (NBDS)," stated RepliCel's Chief Medical Officer, Dr. Rolf Hoffman, "as well as to repeat the landmark trials of our collaborators who injected skin-derived fibroblasts together with PRP (platelet-rich plasma) in different tendinopathies. We believe the cause of healing (mechanism of action) in those studies was the cellular collagen production and not the PRP which, in our view, has little clinical or commercial potential as a therapeutic product or treatment for tendon repair."

"I am very pleased that in this trial we see some early signals of regenerative healing in some patients and because of its similar pathogenesis, there is every reason to believe the ability to heal Achilles tendons will extend to numerous applications including repairing the patellar tendon of the knee (jumper's knee), both tendons of elbow (tennis elbow, golfer's elbow), and the rotator cuff," observed Dr. Hoffmann. "Furthermore," he concluded, "when we have established that our cell therapy heals chronic tendon injury, it may then be used by physicians for more acute injury with the goal of an approved label for these additional treatments in the future."

"This is a major step forward in the Company's development of a series of products which leverage the exciting collagen-producing capacity of these cells," stated RepliCel CEO, Lee Buckler. "Our management and clinical team are very excited about the data from this trial and the potential for further development and clinical testing of this product to treat patients without good options for the tendon degeneration, pain and loss of function they are experiencing."

Buckler concluded: "We have captured the medical and investment communities' attention and see the results of this much anticipated, proof-of-concept clinical study as an opportunity to advance therapies for patients and incrementally add value for shareholders in the months ahead."

[Popeye82]

www.thelifesciencesreport.com/pub/co/4842?utm_source=delivra…

[techinvestor69]

Douglas Loe, Echelon Growth Partners (4/4/17)
"RepliCel Life Sciences Inc. reported interim data this morning from its 17-patient Germany-based Phase I trial evaluating impact from its autologous non-bulbar dermal sheath cell (NBDS)-based therapy RCS-01 on biochemical markers of skin rejuvenation. . .clear evidence that RCS-01 up-regulates biochemical pathways that are known to be relevant to skin rejuvenation, as study design intended. . .the trial absolutely met its primary endpoint of demonstrating safety in patients, with no serious adverse events reported at the time of the trial. . .we continue to maintain our Price Target of $3.50."

[techinvestor69]

Danny Deadlock MicroCap.com Publisher (1998) + Stockhouse.com Ticker Trax, Senior Analyst (2011)

"...The stock is up 10% on this news, but the valuation on RepliCel (RP.V $0.98) at $19M is still appealing. These are early stage results but this discovery may hold significant future value..."

“This type of positive effect on TIMP gene expression, which is related to protection against collagen degeneration, is rarely observed. In my experience, after decades of performing these tests, this is an exceptional finding, particularly for a safety trial with a small sample size,” [Prof. Dr. med Jean Krutmann, Scientific Manager of the IUF Leibniz Research Institute for Environmental Medicine]

[freybel]

Der perfekte Einstiegszeitpunkt?

Wir beobachten zudem seit einigen Monaten ein extrem vielversprechendes Biotechnologieunternehmen, das ein ähnlich explosives Kurspotenzial wie Sirona Biochem aufweisen könnte. Es geht unter anderem um das brisante Thema Haarausfall. Wir denken, dass genau JETZT der perfekte Einstiegszeitpunkt gekommen ist, der Ihnen die exzellente Chance auf eine Kursvervielfachung bietet.

Wäre ja mal Zeit....





Ganzer Text:


http://www.shareribs.com/technology/it-und-kommunikation/ana…

[Schattenwolf]

NEWS

United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market


VANCOUVER, BC – April 25, 2017 - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Company”), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the Company’s novel, multi-needle dermal injection device.

In the development of propriety cell therapy products targeting pattern baldness (androgenetic alopecia) and aging or sun-damaged skin, RepliCel’s dermatology team identified a need for next-generation dermal injection techologies capable of bringing new levels of precision and control to any substances injected into the skin.

The patent issued by the U.S. Patent and Trademark Office (USPTO) relates to technologies designed to enable both unparalleled control and repeatable consistency of needle action and product deposition. The patent also relates to the element designed to numb the skin prior to injection with the intended effect of reducing, if not eliminating, the need for local anesthetic prior to aesthetic injection procedures.

The first device being developed under this patent, RCI-02, is designed for injecting soft tissue fillers such as hyaluronic acid (“HA”). According to recent statistics released by the American Society for Plastic Surgery (April 2017), there were over 11 million minimally invasive cosmetic procedures performed nationally in 2016: over 80% were wrinkle treatments and hyaluronic acid filler injections, totalling an expenditure of over $3 billion.1 RCI-02 represents the nearest-term commercial opportunity for the Company, which it intends to have market-ready and in the hands of a co-development licensee and commercial partner next year (2018).

The device is also being developed for the injection of RepliCel’s RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the device will be optimized for other injectables such as drugs, biologics, vaccines, fat grafts, etc.

The U.S. patent adds to the Company’s intellectual property portfolio, which includes two European patents for RCI-02, both granted February 9, 2017. RepliCel’s first European patent for its injection technologies (Patent No. 2623146) was validated in a total of fourteen countries, including Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Spain, Switzerland, Sweden and the United Kingdom. The second European Patent (No. 2809381) is now being validated in a number of European countries and is expected to be complete in the near future.

“We are confident RepliCel’s extensive patent estate for its cell therapy and injection devices will provide our products with long-term market exclusivity,” said Lee R. Buckler, CEO of RepliCel. “The granting of this U.S. patent is an important addition to RepliCel’s formidable intellectual property portfolio, which we believe will further build value for our investors.”

“Exclusive U.S. rights to the world’s largest aesthetic medical device market represents a significant opportunity for the Company as it addresses an unmet need in the cosmetic dermal injection market,” said Dr. Rolf Hoffmann, RepliCel’s Chief Medical Officer, a practicing dermatologist and the primary inventor of the RCI-02 injector. “Single needle syringes available today do not have the ability to precisely deliver dermal fillers with predictable and consistent results,” he stated.

Dr. Hoffmann continued by saying, “RepliCel’s RCI-02 injector has been designed to provide unprecedented reliability, reproducibility, and programmability of three-dimensional skin injections, enabling clinicians better control and consistency, while also providing less-experienced injection specialists with the confidence to undertake these procedures with desired outcomes.”

“The Company is on track to have prototypes ready in Q3 2017 for initial functional and usability testing by engineers, as well as, user-groups,” continued Mr. Buckler. “This year is about building and testing commercial-grade prototypes. Next year, our goal is to get RCI-02 CE-marked, licensed to a commercial partner and generating revenue.”

About RCI-02
The RCI-02 injector was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes.

RCI-02 is the world’s first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or intramuscularly (muscle) via an array of needle configurations ranging from a single needle to a 16 needle configuration (4x4) on one head. These interchangeable heads can be used to perform a variety of procedures, increase surface area coverage and speed-up procedure times.

By relying on electrical power (instead of thumb pressure) and digital controls, RCI-02 automates and simplifies the injection process. Equipped with a touch screen on its accompanying docking station, the device’s programmability allows for the delivery of precise quantities of material, at specific depths, through fine-gauge needles, on a single plain or trailing through multi-plains, as the needle retracts through the skin.

Overall benefits of this next-generation dermal injector technology are anticipated to include improved handling, reduction or elimination of the need for local anesthetic, quicker procedure times, improved patient experience, and a significant expansion of the areas that can be addressed with dermal fillers due to the ability to conduct broad, shallow and evenly-dispersed injections.

The near-term commercial opportunity for RCI-02 is to improve the injection of hyaluronic acid-based dermal fillers. RepliCel’s dermatologist advisors believe this device has the potential to significantly expand the number of HA dermal injection procedures currently performed. As an example, the HA market in the United States is currently valued at over US$1 billion per year and is growing at near double digits.2 These HA injections primarily address deep facial wrinkles and folds, but do not adequately address fine wrinkles. A device, such as RCI-02, which is capable of delivering a controlled injectable, utilizing a multi-head configuration, and eliminating the need for local anesthetic, has the potential to dramatically increase the HA market into new areas including fine wrinkles of the face, the hands and the décolleté.

About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the company believes is approximately one in three Americans, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. The Company’s product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is currently being co-developed with and under exclusive license by Shiseido for certain Asian countries. All product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles. RepliCel has also developed a proprietary injection device RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications. Please visit http://www.replicel.com/ for additional information.

For more information, please contact:
Lee Buckler, CEO and President
Telephone: [phone] / [e-mail]

References:
1, 2 American Society of Plastic Surgeons (ASPS) Report of 2016 Surgeon/Physician Fees (April 2017) [Press release]. Retrieved from https://www.plasticsurgery.org/news/press-releases/more-than…

[Popeye82]

https://smallcappower.com/editors-picks/replicel-life-scienc…

[pickuru]

Why RepliCel may be the most compelling biotech company to watch in Canada

http://www.bnn.ca/video/why-replicel-may-be-the-most-compell…

[techinvestor69]

Biotech stocks are soaring! The next winner could be RepliCel’s groundbreaking therapies, which could dominate the combined $11 billion hair restoration, skin rejuvenation, and tendon repair markets

http://aimhighreport.com/

[techinvestor69]

RepliCel signs definitive deals with Yofoto

2018-07-11 06:37 ET - News Release

Mr. R. Lee Buckler reports

REPLICEL LIFE SCIENCES ANNOUNCES SIGNED LICENSING AND CO-DEVELOPMENT DEAL FOR GREATER CHINA

RepliCel Life Sciences Inc. has signed definitive agreements with Yofoto (China) Health Industry Co. Ltd., sealing its partnership to commercialize three of RepliCel's programs in Greater China.

The deal between the parties represents an investment in RepliCel by Yofoto along with milestone payments, minimum program financing commitments and sales royalties in exchange for an exclusive 15-year licence to three of RepliCel products for Greater China (Mainland China, Hong Kong, Macau and Taiwan).

The RepliCel-Yofoto collaboration is focused on the development and commercialization in Greater China of RepliCel's tendon regeneration cell therapy (RCT-01), skin rejuvenation cell therapy (RCS-01) and its injection technology in development for dermal applications (RCI-02) (excluding hair-related treatments).

Yofoto's upfront investment will be a $5.09-million purchase of shares at 95 cents per share and will include 20-per-cent warrant coverage exercisable at 95 cents per share for a period of two years. The deal structure also includes milestone payments (of up to $4.75-million), sales royalties, and a commitment by Yofoto to spend a minimum of $7-million on the RepliCel programs and associated cell processing manufacturing facility over the next five years in Greater China.

"In 2017 RepliCel delivered successful phase 1 data in all three of its cell therapy programs and functioning prototypes of its next-generation dermal injector," stated RepliCel president and chief executive officer, R. Lee Buckler. "We were committed to delivering a landmark partnership to RepliCel shareholders in 2018. The partnership with Yofoto represents such a deal and provides RepliCel with not only an outstanding partner in Greater China but capital to move our programs forward in Europe and North America."

"Yofoto is a fast-growing company built on values related to beauty and healthy, active lifestyles," stated Yofoto chairman Huang Jin Bao. "As a key part of developing and commercializing products related to these core values for our consumers, we are committed to being a leader in China in the commercialization of regenerative medicines. The RepliCel cell therapy and injection technologies focused on skin rejuvenation and tendon repair, are important building blocks in Yofoto's strategic health care vision. We are pleased to have structured a deal with RepliCel which results in Yofoto not only being a development partner and commercial licensee but also an investor committed to contributing to RepliCel's global success."

The deposit already paid by Yofoto pursuant to the earlier signing of the binding term sheet remains in escrow pending closing. As part of the transaction, the company has agreed to grant Yofoto certain financing participation rights along with a board seat nomination. Upon Yofoto meeting certain defined conditions, relevant Chinese patents, once issued in China, will be assigned to a Yofoto-owned Canadian subsidiary, with detailed assignment reversion rights upon failure to meet defined targets.

Closing of the transaction represented in the signed agreements between the parties is subject to approval of the TSX Venture Exchange, and other applicable regulatory authorities including but not limited to the reviews and approvals by the State Administration of Foreign Exchange of China and other Chinese foreign investment regulatory authorities.

...

Quelle: www.stockwatch.com

[Popeye82]

https://replicel.com/20180711/

[Popeye82]

www.streetwisereports.com/article/2018/09/26/partnership-gre…

[techinvestor69]

2018-10-15 07:33 ET - Shareholders Letter

Mr. Lee Buckler reports

REPLICEL CEO PROVIDES UPDATED OUTLOOK

RepliCel Life Sciences Inc. has provided an update to shareholders from its president and chief executive officer R. Lee Buckler.

Dear shareholders,

Now that we have closed our deal with YOFOTO, I am very pleased to provide this updated outlook.

In January, I outlined our progress over the past 24 months and included our goals for 2018 which, I said, would be focused on "... leveraging partnerships to drive the company towards maturation." Last week, we announced we had closed an investment with YOFOTO (China) Health Industry Co. Ltd., which is now a significant shareholder and business partner.

This update is intended to provide shareholders with a sense of what this strategic transaction means for RepliCel and an update on our next steps.

Firstly, let us recap the recent news:

For the past eleven months, we have been working toward securing and closing this partnership in Greater China. The valuation at which the upfront investment was made clearly indicates that YOFOTO believes they will help us create considerably more value in the company over the coming months.
YOFOTO has committed to spending a minimum of $7-million on RepliCel's programs and related infrastructure over the next five years in greater China. This includes it financing technology transfer, manufacturing, regulatory submissions and clinical trials in greater China as well as the commercial launch of our dermal injector in greater China. YOFOTO has told us it expects to spend much more than this minimum. YOFOTO has also committed to over $4.5-million in milestone payments, some of which are precommercial and sales royalties.
In addition to financing clinical development and commercialization in greater China as a licensee, YOFOTO is now a significant investor in RepliCel having invested just over $5-million at 95 cents per common share. RepliCel will use the proceeds from this investment to finance its programs in Europe and North America. Additionally, YOFOTO has financing participation rights for two years to maintain its pro rata ownership position which translates into a likely lead order in any private placement that may be needed in the future.

Near-term commercial opportunity

There are two near-term commercial opportunities for RepliCel programs. Firstly, with sufficiently positive data from the RCH-01 clinical study in Japan, Shiseido may be in a position to launch the product in Japan for the treatment of patients with androgenic alopecia. Secondly, YOFOTO is committed to launching the RCI-02 dermal injector in Hong Kong as soon as it is CE marked. The CE mark also presents a significant new partnering opportunity to secure a commercial partnership for the launch of the device in Europe and other countries recognizing the CE mark approval.

Either or both of these potential commercial launches would transition RepliCel from being a prerevenue development company to generating revenue as a commercial entity. This is a material transition in the minds of many retail and institutional investors and is expected to help offset our future development costs for other products.

Development next steps

RepliCel will focus resources and capacities on three priorities in the near-term:

Finalizing the dermal injector to build the commercial-grade prototypes, test and validate its function, and submit an application for a CE mark to enable its commercial launch;
Engaging in the technology transfer work needed from Europe and Canada to set YOFOTO up in China to prepare for clinical trials there as quickly as possible;
Preparing for next-stage clinical trials.

Partnership and business development update

Many shareholders have been asking about the status of our relationship with Shiseido. This remains unchanged from the information provided in September, 2016. This may or may not change if positive clinical data are announced in the coming weeks from the Japanese clinical study and/or if Shiseido announces an intention to commercially launch the product in Japan. We continue to press for a commercial solution with Shiseido that is mutually beneficial.

With the YOFOTO partnership now in place to begin executing our collaboration, I will be turning attention to other strategic corporate opportunities. I firmly believe we are not done on the deal-making front even in the near term. We are in active and promising discussions with other potential partners which I look forward to providing more insights on in the coming months.

The next 18 months

RepliCel shareholders should expect to see an exciting stream of activity and updates coming out of China (financed by YOFOTO) in addition to RepliCel activity with particular focus on its device commercialization (financed by this recent transaction).

In January, I laid out an ambitious plan for what shareholders should watch for in 2018. We are, without question, behind schedule on many of these items because of how long it took us to get to an executed agreement with YOFOTO and to close the associated financing transaction. Some of these milestones will clearly slip into 2019; others we will double our efforts on to catch up and deliver yet this year.

Near-term catalysts to watch for over the next 15 to 18 months include:

Anticipated announcement of clinical results from the Shiseido-funded pattern baldness study in Japan;
Commercial-grade prototypes of the dermal injector built and available for clinical and functional testing;
Launch of clinical testing of the injector at select clinical sites for limited clinical applications;
CE mark of the dermal injector to be followed by a new level of commercial partnership discussions;
Registration of the RCI-02 CE mark in Hong Kong for a commercial launch of the dermal injector by YOFOTO;
A decision from Shiseido on if and when it intends to launch of the RCH-01 in Japan;
Data from the gene marker identification study continuing at University of British Columbia;
Receipt of grant financing to finance further product development;
Completion of YOFOTO's manufacturing facility in Ningbo, China;
Completion of technology transfer of the two licensed cell therapy programs to YOFOTO;
Guidance from Chinese regulators on approvals for clinical trials of RCS-01 (skin rejuvenation) and RCT-01 (tendon regeneration) in China;
A designation from Chinese regulators for the RCI-02 (dermal injector) in mainland China.

As resources permit, we will continue planning with leading experts in North America, Europe and Asia on:

Establishing a regulatory dialogue with the United States Food and Drug Administration;
Finalizing plans for phase 2 clinical trials;
Additional manufacturing optimization projects as we plan for profitable commercialization.

In summary, we have leveraged our accomplishments in 2017 into a new partnership which brings tremendous value to RepliCel shareholders and puts us on a trajectory for great things to come in the coming year. We have a pipeline of activity and news which I believe will demonstrate significant momentum throughout the remainder of the year as we work to deliver on near-term milestones and catalysts including transitioning into a revenue-generating, commercial-stage company with the launch of our first products.

I look forward to getting back on the road, as time permits, to meet with many of you. As always, I warmly welcome your e-mails, phone calls or meeting requests.

Sincerely,

R. Lee Buckler

RepliCel president and chief executive officer

Quelle: https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aRP-26698…

[Popeye82]

www.newswire.ca/news-releases/replicel-ceo-provides-updated-…
www.newswire.ca/news-releases/replicel-life-sciences-complet…
www.streetwisereports.com/article/2018/09/26/partnership-gre…
www.cellandgene.com/doc/challenges-keeping-cell-and-gene-the…
https://biotechnologyfocus.ca/Canadian-technology-and-innova…

[Popeye82]

confessions, of a dangerous Mind









www.newswire.ca/news-releases/replicel-announces-federal-gra…


"Dear Trump (Junior)

With the recent closing of our strategic transaction, we are now turning the page on a new chapter for RepliCel Life Sciences – one which I have been planning for some time and am excited about.

My focus as RepliCel CEO for the past 21 months has been on completing projects already underway when I took over - three phase 1 trials and moving the dermal injector to early functional prototypes. My vision was to take the results from those milestones and define a renewed strategy for RepliCel - one which involved transitioning the company into a commercial enterprise and creating value for RepliCel shareholders through revenue and additional partnerships. With the YOFOTO deal closed, we can now begin executing on this strategy in earnest.

To both represent and drive a renewed vision for RepliCel, going forward we will be doing a number of things differently. Soon you will receive the information circular for our upcoming Annual General Meeting to be held December 14 in Vancouver. In it, you will see some of those changes reflected. We will keep you updated on other changes by way of this newsletter. Some are big, some are small but we are making all of them because we believe they matter.

I am working with the Board, our management team, external partners, and some of you to execute a strategy which thinks and works differently to enhance our results.

Next week I start hitting the road again to speak to investors about our story in the United States and Canada. In December I’ll be speaking with investors in China alongside YOFOTO. The message is clear. We now have a well-capitalized, very motivated partner developing and commercializing products with us in greater China, we anticipate hearing sometime soon about the clinical results from the Shiseido-sponsored hair loss study in Japan, and we are now months away from having commercial-grade units of the dermal injector in our hands. These are things which matter, create value, and will take RepliCel Life Sciences to the next level.

Watch for more news announcements shortly and I hope to see you soon either on the road or at our upcoming AGM.

Sincerely,

Lee"

[Popeye82]

http://www.replicel.com/news/replicel-reignites-its-first-in…

[Popeye82]

http://replicel.com/news/replicel-s-licensee-building-moment…

[Popeye82]

gameOVER.

[Jano82]

Ist hier noch jemand dabei ?
Grüße

[vcxy_]

Antwort auf Beitrag Nr.: 62.130.671 von Jano82 am 11.12.19 11:16:34

Studienergebnisse zu RCH-01

...zumindest kurzfristig wird das nichts:

https://www.sciencedirect.com/science/article/abs/pii/S01909…

Greetz

[Jano82]

Noch jemand Hoffnung das es hier was wird ?
Lg

[vcxy_]

Antwort auf Beitrag Nr.: 64.476.564 von Jano82 am 20.07.20 17:55:00

jo ein steiniger Weg und denen gehen die Kohlen aus. Aber auf der anderen Seite führt Shiseido nochmal eine Stuide durch:

https://jrct.niph.go.jp/en-latest-detail/jRCTb032200148

Die Bewertung von Replicel ist ja bereits ganz unten angekommen. Sprich entweder wird sie 0 oder es erfolgt ein massiver Anstieg - werden wir m.E. dieses Jahr rausfinden ;-)

Greetz

[vcxy_]

https://stockhouse.com/news/press-releases/2020/11/10/replic…

Greetz

[techinvestor69]

In consideration for an investment of CAD $2,700,000 and the payment of all costs related to obtaining FDA approval for Company’s dermal injector and consumables, RepliCel has agreed to issue MainPointe up to an aggregate of four (4) million common shares, a right to participate in RepliCel’s royalty revenue stream up to a defined ceiling, and certain distribution rights of RepliCel Injector Product Line in the United States. The investment will be made as to CAD $500,000 within five (5) days of receipt of conditional approval from the TSX Venture Exchange, CAD $500,000 by December 15, 2020, CAD $700,000 by January 21, 2021, CAD $700,000 by April 21, 2021 and CAD $300,000 by August 21, 2021. The common shares will be priced at the greater of CAD $0.675 or the Discounted Market Price as such term is defined in the Policies of the TSX Venture Exchange.

[vcxy_]

MainPointe Deal done

https://stocksnewsfeed.com/accesswire/replicel-and-mainpoint…

Greetz

[vcxy_]

Corporate Update

https://stockhouse.com/news/press-releases/2021/02/08/replic…

Greetz

[Nanostox]

Sind heut auch eingestiegen.

[Nanostox]

Der Chart sieht ja gut aus gerade.

[vcxy_]

RepliCel Files Notice of Arbitration against Shiseido

https://www.accesswire.com/viewarticle.aspx?id=668473

[vcxy_]

RepliCel Terminates License Agreement with Shiseido

https://www.replicel.com/news/replicel-terminates-license-ag…

Hehe ein spannendes 2022 steht vor der Tür. In Anbetracht dessen, dass Shiseido eine 2 Studie mit RCH-01 durchgeführt hat, lässt mich doch auf einen buy-out hoffen.

Na denn high risk, nächstes Jahr 0 oder 30 Dollar?! ;-)

Greetz